Results 111 to 120 of about 36,344 (217)

Synthesis, Antiparasitic Activity, and ADME Profile of Morpholinephenylbenzamides: A Pharmacological Study Against Chagas Disease and Visceral Leishmaniasis

open access: yesChemMedChem, Volume 21, Issue 19, 14 October 2026.
Hit‐to‐lead optimization of morpholinephenylbenzamides reveals key structure–activity relationships against Trypanosoma cruzi and Leishmania infantum. Potency, selectivity, and ADME properties are differentially improved across the series, identifying compounds 20, 24, and 16 as complementary templates for the future design of dual antiparasitic leads.
Danilo Nascimento Farago   +15 more
wiley   +1 more source

Acyclovir Use and its Surveillance in a General Population

open access: yes, 1990
This study examined the extent and patterns of use of acyclovir in a health maintenance organization (HMO) population. The development and implementation of a system to survey acyclovir users for possible acute adverse effects is also described ...
Hugh H. Tilson   +6 more
core   +1 more source

Antiviral and virucidal activity of Chelidonium majus L. extract compared with Acyclovir against Herpes simplex virus type 1

open access: yesArmaghane Danesh Bimonthly Journal, 2017
Background and aim: Herpes simplex virus is one of the most important human pathogenic viruses that may lead to oral herpes, keratoconjunctivitis and even encephalitis.
M Sadeghpour Natanzi   +2 more
doaj  

Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis

open access: yes, 2009
Purpose. The incidence and clinical significance of herpes simplex virus type 1 (HSV-1) acyclovir resistance were determined in patients with recurrent herpetic keratitis (RHK). Methods.
Remeijer, Lies   +13 more
core   +1 more source

Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity

open access: yes, 2011
The human breast cancer resistance protein (BCRP/ABCG2) is widely expressed in human tissues, including the kidney. In mice, Bcrp1 (murine BCRP ortholog) mediates the transport of acyclovir into breast milk.
Patrina Gunness   +2 more
core   +1 more source

Confusion in Patients with Shingles and Renal Failure: Acyclovir Neurotoxicity or Herpes Encephalitis

open access: yes, 2012
It is not uncommon for patients with shingles and renal failure who develop confusion during the course of therapy. The patient may have suffered from the adverse reaction of acyclovir or have the neurologic complication related to the dermatological ...
HW Ng, CT Pang
core   +1 more source

Baricitinib as Salvage Therapy for Multidrug‐Resistant Chronic Graft‐Versus‐Host Disease

open access: yes
MedComm, Volume 7, Issue 11, November 2026.
Zhuo‐Yu An   +9 more
wiley   +1 more source

Effects of aqueous leaf extract of Telfairia occidentalis on acyclovir induced renal damage in adult Wistar rat

open access: yesJournal of Applied Sciences and Environmental Management
This study investigated the effects of aqueous leaf extract of Telfairia Occidentalis on acyclovir-induced renal damage in the kidneys of adult Wistar rats. A total of thirty adult Wistar rats weighing an average of 200g were used for this study.
A. R. O. Ehimigbai, D. T. Jayeola
doaj  

Exploring the Effectiveness of Acyclovir against Ranaviral Thymidine Kinases: Molecular Docking and Experimental Validation in a Fish Cell Line

open access: yesLife
The effectiveness of acyclovir, a selective anti-herpesvirus agent, was tested both in silico and in vitro against two ranaviruses, namely the European catfish virus (ECV) and Frog virus 3 (FV3).
Richárd Rácz   +3 more
doaj   +1 more source

Improvement of physicochemical parameters of acyclovir using cocrystallization approach

open access: yes, 2016
Acyclovir is an antiviral drug having potent activity against the virus of herpes family and varicella zoster. Unfortunately, drug suffers very poor oral bioavailability (15-30%).
Chirag Pathak (12847650)   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy